Cite

HARVARD Citation

    Home, P. et al. (2021). Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison. Diabetes, obesity & metabolism. 23 (12), pp. 2660-2669. [Online]. 
  
Back to record